Published Erratum
doi: 10.1007/s10620-019-05876-0.
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Affiliations
- PMID: 31642007
- DOI: 10.1007/s10620-019-05876-0
Item in Clipboard
Published Erratum
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
Dig Dis Sci.
2019 Dec.
Abstract
The original version of the article unfortunately contained a couple of errors. In 'methods' section, in 'Outcomes' subsection, the sentence 'Endoscopic remission was defined as an SESCD ≤ 2 in patients with CD and an EMS ≤ 2 in UC patients while off corticosteroids.'
Erratum for
-
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.Dig Dis Sci. 2019 Jun;64(6):1651-1659. doi: 10.1007/s10620-019-05570-1. Epub 2019 Mar 5. Dig Dis Sci. 2019. PMID: 30835029 Free PMC article.
Similar articles
-
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25. Clin Gastroenterol Hepatol. 2018. PMID: 29704680
-
Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.Aliment Pharmacol Ther. 2018 Sep;48(6):626-637. doi: 10.1111/apt.14919. Epub 2018 Jul 31. Aliment Pharmacol Ther. 2018. PMID: 30063077
-
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).Scand J Gastroenterol. 2018 Feb;53(2):158-167. doi: 10.1080/00365521.2017.1416160. Epub 2017 Dec 19. Scand J Gastroenterol. 2018. PMID: 29258369
-
Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother. 2014 Dec;48(12):1629-35. doi: 10.1177/1060028014549799. Epub 2014 Sep 3. Ann Pharmacother. 2014. PMID: 25186623 Review.
-
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.Clin Pharmacokinet. 2017 Nov;56(11):1287-1301. doi: 10.1007/s40262-017-0546-0. Clin Pharmacokinet. 2017. PMID: 28523450 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
